TRVI vs TYRA

Trevi Therapeutics, Inc. vs Tyra Biosciences, Inc. — Valuation Comparison 2026

TRVI

Pharmaceutical Preparations
Trevi Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
30
LOW
Price
$14.14
Last close
Models
7/13
Active
VS

TYRA

Pharmaceutical Preparations
Tyra Biosciences, Inc.
Quality
4.3
out of 10
Value Trap
18
SAFE
Price
$33.41
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TRVI Fair ValueTRVI Upside TYRA Fair ValueTYRA Upside
Bayesian DCF Intrinsic $3.83 -72.9% $9.65 -71.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.36 -97.4% $1.50 -95.5%
Dynamic NAV Asset-Based $1.06 -92.5% $5.32 -84.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TRVI vs TYRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TRVI vs TYRA — Which Stock Is More Undervalued?

TYRA scores higher with a 4.3/10 quality rating vs TRVI's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Trevi Therapeutics, Inc. (TRVI) and Tyra Biosciences, Inc. (TYRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TRVI currently trades at $14.14 with a QOC of 4.2/10, while TYRA trades at $33.41 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).